Exelixis, Inc. reported STELLAR-303 trial results for zanzalintinib plus atezolizumab vs. regorafenib in mCRC. Learn more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback